Full-Time

Senior Manager Project Management

Project Management

Posted on 10/1/2025

Deadline 10/17/25
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

No salary listed

Germany

In Person

Category
Business & Strategy (1)
Required Skills
Word/Pages/Docs
Risk Management
Excel/Numbers/Sheets
Requirements
  • Bachelor Science degree in engineering required
  • Project Management Professional (PMP) or equivalent required
  • Proficient in Microsoft Outlook, Word, Excel, Microsoft Project and PowerPoint required
  • Minimum of 7 years of Project Management experience
  • Prior experience managing medium to large capital projects in Supply Chain, R&D, Distribution Centers or Offices
  • Understands business needs and can translate these to engineering concepts
  • Technically knowledgeable, can relate to and understand complex technology-based issues
  • Ability to naturally lead and motivate remote and virtual teams and stakeholders
  • Process-oriented, process knowledgeable
  • Excellent listening and problem-solving skills when managing potential conflicts within regions when implementing global standards and guidelines
  • Understanding complex technical/regulatory issues impacting products
  • Track record of developing and maintaining strong partnerships at all levels within the organization, internally (Real Estate, Facilities Management) and with Business partners (CCFS/ Finance/ Engineering/ Operations)
  • Good working knowledge of Project Controls in cost and schedule development, financial assessments and managing of Budget and Schedule
  • Manufacturing experience in FDA or other regulated environments from design through startup
  • Experience and skills on contracting and negotiation
  • Track record in good collaboration with Real Estate, Finance and Facilities Management
Responsibilities
  • Takes Project Lead on Projects at appropriate stages of Ideation, Design, Execution and Assessment
  • Builds collaboration across other functional areas with Business Partners
  • Builds alignment with Sponsor, and shares management of Key Stakeholders, aligns Core and Extended team to deliver the Final Project Objectives
  • Builds communication with the Sponsor and agrees on communication to Key Stakeholders on all aspects of projects, establishes project communication plan and prepares and presents information for Key stakeholders in alignment with Sponsor
  • Manages the project planning, tracking and reporting against project Key Deliverables and Final Project Objectives
  • Establishes Key Performance Indicators and puts plans are in place to meet and identify areas for improvement
  • Facilitates the project intake process, assisting in solutioning and how projects should meet the Business Need, Prepares for Stage Gates, and the development of the selected option for CAR approval
  • Determines appropriate project functions, resources and strategies for the Project Delivery Processes and tools via a Project Execution Plan, based on the complexity of the project business strategies, policy, regulations and all local and national legislation
  • Develops Risk Management methodology to identify, evaluate and manage risks to Final Project Objectives, including resource issues, conflicts and other obstacles, aligning with Sponsors, Functional Managers, Core and Extended Team members to establish appropriate resources
  • Facilitates and Coordinates the design, execution and close out of all project related activities including managing internal resources and the procurement of third-party contractors, suppliers and consultants and tracking the project against plan to ensure delivery of Final Project Objectives. including, but not limited to safety, scope management, contract and construction management, legal and corporate compliance, quality, project controls, commissioning, qualification and validation of FDA and other agencies regulated facilities including technology transfer and regulations governing product manufacturing thru operational handover
  • Identifies potential changes and manages the requests with the Sponsor, Core and Extended teams
  • Facilitates Project Close Out activities ensuring operational handover archiving, and financial project close and collation of benchmarking and lessons Learned and provide feedback to ensure continuous improvement via learnings collection and learnings adoption
  • Identifies key Learning and Development to enable progression to Highly Capable Leadership
  • Assists in the facilitation of the evaluation of the value delivered versus the value identified in the Business Need, collating lessons learned from a Business perspective
Desired Qualifications
  • Familiarity with J&J Project Management approaches (FPX & Project Delivery Process)

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue hit $24.1 billion, up 9.9%, raising 2026 forecast to $100.8 billion.
  • Nipocalimab gains FDA Priority Review for autoimmune hemolytic anemia and myasthenia gravis efficacy.
  • Shockwave C2 Aero launches in US and Japan targeting 315 million calcified CAD patients.

What critics are saying

  • Stelara sales plunge 60% to $656 million in Q1 2026 post-patent expiration, creating $2.3 billion hole.
  • Icotyde stalls at 1,500 prescriptions, missing oncology targets by Q3 2026.
  • CAPLYTA faces Invega Sustenna competition, achieving under 10% adoption by mid-2027.

What makes Johnson & Johnson unique

  • J&J unites Innovative Medicine and MedTech under single brand since September 2023.
  • DARZALEX and TREMFYA dominate oncology and immunology with $57 billion pharma sales in 2024.
  • CARTO System leads electrophysiology for 30 years with AI-powered CARTOSOUND SONATA.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Company News

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.

Yahoo Finance
Apr 1st, 2026
J&J takes over NBTXR3 Phase III as Nanobiotix shifts to Curadigm, secures runway into early 2028

Nanobiotix has transferred full operational and financial responsibility for its NBTXR3 radioenhancer programme to Johnson & Johnson, with Phase III head-and-neck results expected in H1 2027 and Phase II lung cancer data anticipated in early 2027. The company is pivoting towards its Curadigm nanoprimer platform, filing four patents, starting GMP manufacturing and signing over 20 material transfer agreements with partners. Additional Curadigm data is expected before summer's end. An amended Janssen licence removing most Phase III funding obligations, combined with a royalty financing of up to $71 million, extends Nanobiotix's cash runway into early 2028. The company reported EUR 32.6 million revenue in 2025, reduced R&D spending to EUR 23.1 million, and EUR 52.8 million cash at year-end.

INACTIVE